Drugs / GSK2879552
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02177812 | Aug 2014 → Dec 2017 | acute myeloid leukemia | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 1 | NCT02034123 | Feb 2014 → Apr 2017 | small cell carcinoma | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02929498 | Jul 2017 → Jan 2018 | myelodysplastic syndrome | GlaxoSmithKline | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2015-11-03 | GlaxoSmithKline | Results GSK profiles innovative R&D portfolio to investors gsk.com ↗
The phase I studies have shown an early signal of significant progression-free survival for some patients with SCLC. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2015-11-03 | GlaxoSmithKline | GSK profiles innovative R&D portfolio to investors gsk.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK2879552 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02177812 ↗ |
| Action | Inhibit | “lysine specific demethylase 1 (LSD1) inhibitor GSK2879552” NCT02177812 ↗ |
| Modality | Small molecule | — CHEMBL3786182 ↗ |
| Route | Oral | “Subjects will receive GSK2879552orally with approximately 200 milliliter (mL) of water.” NCT02034123 ↗ |